2026-11-17 量子科学技術研究開発機構
<関連情報>
- https://www.qst.go.jp/site/press/20261117.html
- https://www.neurology.org/doi/10.1212/WNL.0000000000218693
進行性核上性麻痺患者におけるタウ病理、脳萎縮および症状領域の生体内トポグラフィー上の関連
In Vivo Topographic Associations Between Tau Pathology, Atrophy, and Symptom Domains in Patients with Progressive Supranuclear Palsy
Yuko Kataoka, Ryoji Goto, Yoshikazu Chishiki, Kenta Osawa, Asaka Oyama, Hideki Matsumoto, ほか(最終著者:Hironobu Endo)Neurology, 107(11), e218693 2026-11-16
DOI:10.1212/WNL.0000000000218693
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder characterized by the accumulation of 4-repeat tau protein and associated with ocular motor dysfunction, gait and postural instability, and limb motor impairments. This study investigated the relationships between tau pathology, regional brain atrophy, and distinct symptom domains using florzolotau (18F) positron emission tomography (PET) and structural magnetic resonance imaging (MRI) in 58 patients with PSP and 52 healthy controls. The results demonstrated substantial spatial overlap between tau accumulation and brain atrophy in subcortical structures, particularly the midbrain and basal ganglia. Symptom-specific analyses revealed that ocular motor dysfunction was associated with tau deposition and atrophy in the midbrain tegmentum and globus pallidus, whereas gait and midline impairments were associated with tau accumulation in the globus pallidus, thalamus, and subthalamic nucleus. In contrast, limb motor impairments were associated with tau accumulation in the primary motor and somatosensory cortices, while corresponding brain atrophy was predominantly observed in the angular gyrus, supramarginal gyrus, and temporal lobes. These findings indicate that tau pathology and neuronal loss may have distinct spatial relationships across different clinical symptom domains. Exploratory path analyses further suggested that the associations among tau accumulation, regional atrophy, and symptom severity may vary according to disease duration. This study provides symptom-specific in vivo maps of tau pathology and neurodegeneration, potentially supporting a better understanding of PSP pathophysiology, patient stratification, clinical trials of tau-targeted therapies, and the development of imaging biomarkers. However, the single-center cross-sectional design limits causal and temporal interpretations, which require confirmation through longitudinal studies.
